ºÝºÝߣ

ºÝºÝߣShare a Scribd company logo
HEPATIC
ENCEPHALOPATHY
Dr. Reena
Residant Ward 6
Definition
• It is a state of disordered CNS function, resulting from
failure of liver to detoxify toxic agents because of hepatic
insufficiency and porto-systemic shunt.
• It represents a reversible decrease in neurologic function.
• It occurs most often in patients with cirrhosis but also
occur in acute hepatic failure.
Pathogenesis
• Ammonia formed by protein breakdown in GIT
• Liver liver dysfunction (abnormal) NH3 Passes
BBB Hepatic encephalopathy.
• Other factors:
• Increase sensitivity to glutamine & GABA (inhibitory
neurotransmitter)
• Increase circulating levels of endogenous
benzodiazepines.
Pathogenesis (acute & chronic )
The basic cause is same in both forms but the mechanism is somewhat
different
Diminished detoxification of toxic intestinal nitrogenous compounds
Increased in blood
NH3 etc
Toxic effect on
brain
Appearance of
abnormal amines in
systemic circulation
Interference with
neurotransmission
Endotoxins
• Ammonia.
• Mercaptans (degradation of methionine in the gut)
• Phenols.
• Free fatty acids.
• Gamma amino butyric acid(GABA)
• Octopamine.
Causes
• Chronic parenchymal liver disease:
• Chronic hepatitis.
• Cirrhosis.
• Fulminating hepatic failure:
• Acute viral hepatitis.
• Drugs.
• Toxins e.g. Wilson’s Disease, CCL4.
• Surgical Portal-systemic anastomoses, - portacaval
shunts, or Transjugular intrahepatic portal-systemic
shunting [TIPS]).
Precipitating Agents
• (A) Increase Nitrogen Load
(a) Constipation.
(b) Gastro intestinal bleeding.
(c) Excess dietary intake of protein & fatty acids.
(d) Azotemia.
Precipitating Agents
• (B) Infections & Trauma (Surgery)
• (C) Electrolyte & Metabolic imbalance
• Hypokalemia.
• Alkalosis.
• Hypoxia.
• Hyponatremic.
Precipitating Agents
• (D) Drugs
• Diuretics.
• Narcotics, Tranquilizers, Sedatives.
Clinical Features
• A Disturbance in consciousness
• Disturbances in sleep rhythm.
• Impaired memory/ apraxia.
• Mental confusion.
• Apathy.
• Drowsiness / Somnolence.
• Coma.
• B. Changes Personality
• Childish behavior.
• May be aggressive out burst.
• Euphoric.
• Foetor hepaticus – Foul–smelling breath associated
with liver disease due to mercaptans.
• C Neurological signs:
• Flapping tremor / Asterixis (in pre coma).
• Exaggerated tendon reflex.
• Extensor plantar reflex.
Clinical Staging
Hepatic encephalopathy
Hepatic encephalopathy
Investigation
• Diagnosis is usually made clinically
• Routine Investigations - CBC, LFTS, Electolytes, Urea,
Creatinine, Prothrombin time, Albumin , A/G ratio.
• Elevation of blood ammonia.
• EEG (Electroencephalogram)
• CSF & CT Scan – Normal.
Differential Diagnosis
• Subdural Haematoma.
• Drug or Alcohol intoxication.
• Wernicke’s encephalopathy.
• Hypoglycaemia.
Management
• Supportive Treatment.
• Specific Treatment aims at:
• Decreasing ammonia production in colon
• Elimination or treatment of precipitating factors.
Hepatic encephalopathy
TREATMENT
• Hospitalize the patient.
• Maintain ABC.
• Identify and remove the precipitating factors.
• Iv fluid dextrose ,saline.
• Stop Diuretic Therapy.
• Correct any electrolyte imbalance.
• Ryle tube feeding & bladder catheterization.
• Reduce the ammonia (NH3) Load.
• Diet – Restriction of protein diet.
High glucose diet.
• Treat Constipation by Laxatives.
Lactulose
• Lactulose 15-30ml X 3 – 4 times a day- result aims at 2-4
stools/day.
• Rectal use is indicated when patient is unable to take
orally.
• 300ml of lactulose in 700ml of saline or sorbitol as a
retention enema for 30 – 60 min.
• May be repeated 4 – 6 hours.
Mechanism of action of Lactulose
• A non-absorbable disaccharide.
• It produces osmosis of water- Diarrhea.
• It reduces pH of colonic content & thereby prevents
absorption of NH3.
• It converts NH3- NH4 that can be excreted.
Treat the GIT & other Infections
Antibiotics:
• Rifaximin
• Broad spectrum antibiotic, recently approved in humans
for HE.
• Negligible systemic absorption.
• Shown to decrease hospitalizations and length of stay as
compared to lactulose in humans.
• DOSE: 550 mg orally B.I.D
• Metronidazole : 250mg orally T.D.S
• Neomycin : 0.5 – 1 g orally 6 or 12 hours for 7 days.
• Side effects: Ototoxicity, nephrotoxicity.
• Vancomycin : 1 g orally B.I.D
DIET
• With held dietary protein during acute episode if patient
cannot eat.
• Oral intake should be 60 – 80 g/day as tolerated.
• Vagetable protein is better tolerated than meat protein.
• G.I.T bleeding should be controlled
• 120ml of magnesium citrate by mouth or NG tube every 3
– 4 hours until stool free of blood.
Stimulation of metabolic ammonia
metabolism:
• Sodium benzoate
• 5 g orally twice a day.
• L-ornithine-L-aspartate
• 9 g orally thrice a day.
• L-acyl-carnitine aspartate
• 4 g orally daily.
• Zinc sulphate
• 600mg/day in divided doses.
Correct amino acid metabolic
imbalance
• Infusion or oral administration of BCAA
(branched-chain amino acid)
• Its use is unnecessary except in patient who are intolerant
of standard protein supplements.
GABA/BZ complex antagonist:
• Flumazenil ( particularly if patient has been given
banzodiazepines )
• Opiods & sedatives should be avoided.
Acarbose
• α – glucosidase inhibitor.
• Under study.
• Other Therapies:
• Prebiotics & probiotics.
• Extracorporeal albumin dialysis ( MARS)
• Liver transplant.
PROGNOSIS
• Acute hepatic encephalopathy may be treatable.
• Chronic forms of the disorder often keep getting worse or
continue to come back.
• Both forms may result in irreversible coma and death.
• Approximately 80% (8 out of 10 patients) die if they go
into a coma.
• Recovery & the risk of the condition returning vary from
patient to patient
REFERENCES
• Davidson’s Principles & Practice of Medicine- 21st edition.
• Harrison’s Principles of internal Medicine-10th & 17th
edition.
• Current Medical Diagnosis & Treatment – 2014 edition.
Hepatic encephalopathy

More Related Content

What's hot (20)

Pheochromocytoma
PheochromocytomaPheochromocytoma
Pheochromocytoma
rashree-singh
Ìý
Cholelithiasis
CholelithiasisCholelithiasis
Cholelithiasis
Nikhil Gupta
Ìý
Ulcerative colitis
Ulcerative colitisUlcerative colitis
Ulcerative colitis
syed ubaid
Ìý
Fulminant hepatic failure
Fulminant hepatic failureFulminant hepatic failure
Fulminant hepatic failure
Ranjithkumar Kondapaka
Ìý
Obstructive jaundice
Obstructive jaundiceObstructive jaundice
Obstructive jaundice
Bashir BnYunus
Ìý
Inguinal hernia
Inguinal herniaInguinal hernia
Inguinal hernia
fathimma sahir
Ìý
Management of seizures
Management of seizuresManagement of seizures
Management of seizures
Praveen Nagula
Ìý
Cholecystitis
CholecystitisCholecystitis
Cholecystitis
Vikrant Udutha
Ìý
Cushing Syndrome
Cushing SyndromeCushing Syndrome
Cushing Syndrome
Dr. Binu Babu Nursing Lectures Incredibly Easy
Ìý
Liver abscess
Liver abscessLiver abscess
Liver abscess
Jibran Mohsin
Ìý
Chronic liver disease
Chronic liver diseaseChronic liver disease
Chronic liver disease
Puneet Shukla
Ìý
chronic liver disease (CLD)
chronic liver disease (CLD)chronic liver disease (CLD)
chronic liver disease (CLD)
Kashif Hussain
Ìý
Achalasia
AchalasiaAchalasia
Achalasia
fareedresidency
Ìý
Esophageal varices
Esophageal varicesEsophageal varices
Esophageal varices
Shweta Sharma
Ìý
RECTAL PROLAPSE
RECTAL PROLAPSE RECTAL PROLAPSE
RECTAL PROLAPSE
Kushal kumar
Ìý
Status Epilepticus
Status EpilepticusStatus Epilepticus
Status Epilepticus
Zeeshan Khan
Ìý
Obstructive jaundice
Obstructive jaundiceObstructive jaundice
Obstructive jaundice
Silah Aysha
Ìý
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS, Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
pankaj rana
Ìý
Intestinal obstruction
Intestinal obstructionIntestinal obstruction
Intestinal obstruction
syed ubaid
Ìý
Abdiminal tuberculosis
Abdiminal tuberculosisAbdiminal tuberculosis
Abdiminal tuberculosis
Thorlikonda Sasidhar
Ìý
Pheochromocytoma
PheochromocytomaPheochromocytoma
Pheochromocytoma
rashree-singh
Ìý
Cholelithiasis
CholelithiasisCholelithiasis
Cholelithiasis
Nikhil Gupta
Ìý
Ulcerative colitis
Ulcerative colitisUlcerative colitis
Ulcerative colitis
syed ubaid
Ìý
Obstructive jaundice
Obstructive jaundiceObstructive jaundice
Obstructive jaundice
Bashir BnYunus
Ìý
Management of seizures
Management of seizuresManagement of seizures
Management of seizures
Praveen Nagula
Ìý
Chronic liver disease
Chronic liver diseaseChronic liver disease
Chronic liver disease
Puneet Shukla
Ìý
chronic liver disease (CLD)
chronic liver disease (CLD)chronic liver disease (CLD)
chronic liver disease (CLD)
Kashif Hussain
Ìý
Esophageal varices
Esophageal varicesEsophageal varices
Esophageal varices
Shweta Sharma
Ìý
RECTAL PROLAPSE
RECTAL PROLAPSE RECTAL PROLAPSE
RECTAL PROLAPSE
Kushal kumar
Ìý
Status Epilepticus
Status EpilepticusStatus Epilepticus
Status Epilepticus
Zeeshan Khan
Ìý
Obstructive jaundice
Obstructive jaundiceObstructive jaundice
Obstructive jaundice
Silah Aysha
Ìý
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS, Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
Pyelonephritis, ACUTE PYELONEPHRITIS, CHRONIC PYELONEPHRITIS,
pankaj rana
Ìý
Intestinal obstruction
Intestinal obstructionIntestinal obstruction
Intestinal obstruction
syed ubaid
Ìý

Similar to Hepatic encephalopathy (20)

Hepatic encephalopathy [HE]
Hepatic encephalopathy [HE]Hepatic encephalopathy [HE]
Hepatic encephalopathy [HE]
Deepak Pradeep
Ìý
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
Arun George
Ìý
LECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LECTURE HEPATIC ENCEPHALOPATHY for study.pptLECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LivoJoe1
Ìý
Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien
Kafrelsheiekh University
Ìý
urea cycle.pptx
urea cycle.pptxurea cycle.pptx
urea cycle.pptx
SanthiMeherPeddi
Ìý
Metabolic 5 5-2013
Metabolic 5 5-2013Metabolic 5 5-2013
Metabolic 5 5-2013
Azad Haleem
Ìý
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptxFULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
priyanka060900
Ìý
20110722 - Czaja - LFTs.ppt
20110722 - Czaja - LFTs.ppt20110722 - Czaja - LFTs.ppt
20110722 - Czaja - LFTs.ppt
HassanWajid4
Ìý
Case Discussion Chronic Pancreatitis Metages.pptx
Case Discussion Chronic Pancreatitis Metages.pptxCase Discussion Chronic Pancreatitis Metages.pptx
Case Discussion Chronic Pancreatitis Metages.pptx
MisaleHaile
Ìý
APPROACH TO ABNORMAL LFT
APPROACH TO ABNORMAL LFTAPPROACH TO ABNORMAL LFT
APPROACH TO ABNORMAL LFT
Navas Shareef
Ìý
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
Bikash Praharaj
Ìý
Antigout pharmacology. Medicine use in gout
Antigout pharmacology. Medicine use in goutAntigout pharmacology. Medicine use in gout
Antigout pharmacology. Medicine use in gout
Pawan Maharjan
Ìý
Alcoholic liver disease
Alcoholic liver diseaseAlcoholic liver disease
Alcoholic liver disease
Kiran Bikkad
Ìý
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptxINFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
asmitapandey5196
Ìý
Acute liver failure in children
Acute liver failure in childrenAcute liver failure in children
Acute liver failure in children
Ramsha Baig
Ìý
Hepatic Failure & Hepato Renal Syndrome.pptx
Hepatic Failure & Hepato Renal Syndrome.pptxHepatic Failure & Hepato Renal Syndrome.pptx
Hepatic Failure & Hepato Renal Syndrome.pptx
drhardikastik1
Ìý
A review of liver anatomy and physiology for anesthesiologists
A review of liver anatomy and physiology for anesthesiologistsA review of liver anatomy and physiology for anesthesiologists
A review of liver anatomy and physiology for anesthesiologists
Arun Shetty
Ìý
Dyselectrolytemias
DyselectrolytemiasDyselectrolytemias
Dyselectrolytemias
Dr Sunit Lokwani
Ìý
Liver function tests interpretation bilirubin metabolism
Liver function tests interpretation bilirubin metabolismLiver function tests interpretation bilirubin metabolism
Liver function tests interpretation bilirubin metabolism
DrMAnwar2
Ìý
Recent advances in renal ...
Recent advances in renal                                                     ...Recent advances in renal                                                     ...
Recent advances in renal ...
kalpanatiwari17
Ìý
Hepatic encephalopathy [HE]
Hepatic encephalopathy [HE]Hepatic encephalopathy [HE]
Hepatic encephalopathy [HE]
Deepak Pradeep
Ìý
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
Arun George
Ìý
LECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LECTURE HEPATIC ENCEPHALOPATHY for study.pptLECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LECTURE HEPATIC ENCEPHALOPATHY for study.ppt
LivoJoe1
Ìý
Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien
Kafrelsheiekh University
Ìý
Metabolic 5 5-2013
Metabolic 5 5-2013Metabolic 5 5-2013
Metabolic 5 5-2013
Azad Haleem
Ìý
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptxFULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
FULMINANT HEPATIC FAILURE AND ITS COMPLICATIONS.pptx
priyanka060900
Ìý
20110722 - Czaja - LFTs.ppt
20110722 - Czaja - LFTs.ppt20110722 - Czaja - LFTs.ppt
20110722 - Czaja - LFTs.ppt
HassanWajid4
Ìý
Case Discussion Chronic Pancreatitis Metages.pptx
Case Discussion Chronic Pancreatitis Metages.pptxCase Discussion Chronic Pancreatitis Metages.pptx
Case Discussion Chronic Pancreatitis Metages.pptx
MisaleHaile
Ìý
APPROACH TO ABNORMAL LFT
APPROACH TO ABNORMAL LFTAPPROACH TO ABNORMAL LFT
APPROACH TO ABNORMAL LFT
Navas Shareef
Ìý
Hepatic encephalopathy
Hepatic encephalopathyHepatic encephalopathy
Hepatic encephalopathy
Bikash Praharaj
Ìý
Antigout pharmacology. Medicine use in gout
Antigout pharmacology. Medicine use in goutAntigout pharmacology. Medicine use in gout
Antigout pharmacology. Medicine use in gout
Pawan Maharjan
Ìý
Alcoholic liver disease
Alcoholic liver diseaseAlcoholic liver disease
Alcoholic liver disease
Kiran Bikkad
Ìý
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptxINFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
INFLAMMATORY BOWEL DISEASE-UC,CD DRUGS.pptx
asmitapandey5196
Ìý
Acute liver failure in children
Acute liver failure in childrenAcute liver failure in children
Acute liver failure in children
Ramsha Baig
Ìý
Hepatic Failure & Hepato Renal Syndrome.pptx
Hepatic Failure & Hepato Renal Syndrome.pptxHepatic Failure & Hepato Renal Syndrome.pptx
Hepatic Failure & Hepato Renal Syndrome.pptx
drhardikastik1
Ìý
A review of liver anatomy and physiology for anesthesiologists
A review of liver anatomy and physiology for anesthesiologistsA review of liver anatomy and physiology for anesthesiologists
A review of liver anatomy and physiology for anesthesiologists
Arun Shetty
Ìý
Liver function tests interpretation bilirubin metabolism
Liver function tests interpretation bilirubin metabolismLiver function tests interpretation bilirubin metabolism
Liver function tests interpretation bilirubin metabolism
DrMAnwar2
Ìý
Recent advances in renal ...
Recent advances in renal                                                     ...Recent advances in renal                                                     ...
Recent advances in renal ...
kalpanatiwari17
Ìý

Recently uploaded (20)

ASP.NET Interview Questions PDF By ScholarHat
ASP.NET  Interview Questions PDF By ScholarHatASP.NET  Interview Questions PDF By ScholarHat
ASP.NET Interview Questions PDF By ScholarHat
Scholarhat
Ìý
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdfNUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
Dolisha Warbi
Ìý
Administrative bodies( D and C Act, 1940
Administrative bodies( D and C Act, 1940Administrative bodies( D and C Act, 1940
Administrative bodies( D and C Act, 1940
P.N.DESHMUKH
Ìý
Year 10 The Senior Phase Session 3 Term 1.pptx
Year 10 The Senior Phase Session 3 Term 1.pptxYear 10 The Senior Phase Session 3 Term 1.pptx
Year 10 The Senior Phase Session 3 Term 1.pptx
mansk2
Ìý
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAHBISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
coacharyasetiyaki
Ìý
How to Configure Proforma Invoice in Odoo 18 Sales
How to Configure Proforma Invoice in Odoo 18 SalesHow to Configure Proforma Invoice in Odoo 18 Sales
How to Configure Proforma Invoice in Odoo 18 Sales
Celine George
Ìý
OOPs Interview Questions PDF By ScholarHat
OOPs Interview Questions PDF By ScholarHatOOPs Interview Questions PDF By ScholarHat
OOPs Interview Questions PDF By ScholarHat
Scholarhat
Ìý
CRITICAL THINKING AND NURSING JUDGEMENT.pptx
CRITICAL THINKING AND NURSING JUDGEMENT.pptxCRITICAL THINKING AND NURSING JUDGEMENT.pptx
CRITICAL THINKING AND NURSING JUDGEMENT.pptx
PoojaSen20
Ìý
Interim Guidelines for PMES-DM-17-2025-PPT.pptx
Interim Guidelines for PMES-DM-17-2025-PPT.pptxInterim Guidelines for PMES-DM-17-2025-PPT.pptx
Interim Guidelines for PMES-DM-17-2025-PPT.pptx
sirjeromemanansala
Ìý
Blind spots in AI and Formulation Science, IFPAC 2025.pdf
Blind spots in AI and Formulation Science, IFPAC 2025.pdfBlind spots in AI and Formulation Science, IFPAC 2025.pdf
Blind spots in AI and Formulation Science, IFPAC 2025.pdf
Ajaz Hussain
Ìý
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
SONU HEETSON
Ìý
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
Prof. (Dr.) Vinod Kumar Kanvaria
Ìý
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
EduSkills OECD
Ìý
Full-Stack .NET Developer Interview Questions PDF By ScholarHat
Full-Stack .NET Developer Interview Questions PDF By ScholarHatFull-Stack .NET Developer Interview Questions PDF By ScholarHat
Full-Stack .NET Developer Interview Questions PDF By ScholarHat
Scholarhat
Ìý
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.pptAnnex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
joan dalilis
Ìý
Cyrus_Kelisha_SMM_PB1_2024-November.pptx
Cyrus_Kelisha_SMM_PB1_2024-November.pptxCyrus_Kelisha_SMM_PB1_2024-November.pptx
Cyrus_Kelisha_SMM_PB1_2024-November.pptx
KelishaCyrus
Ìý
teacher activies un classroom and students
teacher activies un classroom and studentsteacher activies un classroom and students
teacher activies un classroom and students
prabowoedy1
Ìý
Azure Data Engineer Interview Questions By ScholarHat
Azure Data Engineer Interview Questions By ScholarHatAzure Data Engineer Interview Questions By ScholarHat
Azure Data Engineer Interview Questions By ScholarHat
Scholarhat
Ìý
Helping Autistic Girls Shine Webinar ºÝºÝߣs
Helping Autistic Girls Shine Webinar ºÝºÝߣsHelping Autistic Girls Shine Webinar ºÝºÝߣs
Helping Autistic Girls Shine Webinar ºÝºÝߣs
Pooky Knightsmith
Ìý
PUBH1000 - Module 2: Public Health History
PUBH1000 - Module 2: Public Health HistoryPUBH1000 - Module 2: Public Health History
PUBH1000 - Module 2: Public Health History
Jonathan Hallett
Ìý
ASP.NET Interview Questions PDF By ScholarHat
ASP.NET  Interview Questions PDF By ScholarHatASP.NET  Interview Questions PDF By ScholarHat
ASP.NET Interview Questions PDF By ScholarHat
Scholarhat
Ìý
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdfNUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
NUTRITIONAL ASSESSMENT AND EDUCATION - 5TH SEM.pdf
Dolisha Warbi
Ìý
Administrative bodies( D and C Act, 1940
Administrative bodies( D and C Act, 1940Administrative bodies( D and C Act, 1940
Administrative bodies( D and C Act, 1940
P.N.DESHMUKH
Ìý
Year 10 The Senior Phase Session 3 Term 1.pptx
Year 10 The Senior Phase Session 3 Term 1.pptxYear 10 The Senior Phase Session 3 Term 1.pptx
Year 10 The Senior Phase Session 3 Term 1.pptx
mansk2
Ìý
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAHBISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
BISNIS BERKAH BERANGKAT KE MEKKAH ISTIKMAL SYARIAH
coacharyasetiyaki
Ìý
How to Configure Proforma Invoice in Odoo 18 Sales
How to Configure Proforma Invoice in Odoo 18 SalesHow to Configure Proforma Invoice in Odoo 18 Sales
How to Configure Proforma Invoice in Odoo 18 Sales
Celine George
Ìý
OOPs Interview Questions PDF By ScholarHat
OOPs Interview Questions PDF By ScholarHatOOPs Interview Questions PDF By ScholarHat
OOPs Interview Questions PDF By ScholarHat
Scholarhat
Ìý
CRITICAL THINKING AND NURSING JUDGEMENT.pptx
CRITICAL THINKING AND NURSING JUDGEMENT.pptxCRITICAL THINKING AND NURSING JUDGEMENT.pptx
CRITICAL THINKING AND NURSING JUDGEMENT.pptx
PoojaSen20
Ìý
Interim Guidelines for PMES-DM-17-2025-PPT.pptx
Interim Guidelines for PMES-DM-17-2025-PPT.pptxInterim Guidelines for PMES-DM-17-2025-PPT.pptx
Interim Guidelines for PMES-DM-17-2025-PPT.pptx
sirjeromemanansala
Ìý
Blind spots in AI and Formulation Science, IFPAC 2025.pdf
Blind spots in AI and Formulation Science, IFPAC 2025.pdfBlind spots in AI and Formulation Science, IFPAC 2025.pdf
Blind spots in AI and Formulation Science, IFPAC 2025.pdf
Ajaz Hussain
Ìý
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
RRB ALP CBT 2 Mechanic Motor Vehicle Question Paper (MMV Exam MCQ)
SONU HEETSON
Ìý
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
AI and Academic Writing, Short Term Course in Academic Writing and Publicatio...
Prof. (Dr.) Vinod Kumar Kanvaria
Ìý
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
Hannah Borhan and Pietro Gagliardi OECD present 'From classroom to community ...
EduSkills OECD
Ìý
Full-Stack .NET Developer Interview Questions PDF By ScholarHat
Full-Stack .NET Developer Interview Questions PDF By ScholarHatFull-Stack .NET Developer Interview Questions PDF By ScholarHat
Full-Stack .NET Developer Interview Questions PDF By ScholarHat
Scholarhat
Ìý
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.pptAnnex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
Annex-A_PMES-Tool-for-Proficient-Teachers-SY-2024-2025.ppt
joan dalilis
Ìý
Cyrus_Kelisha_SMM_PB1_2024-November.pptx
Cyrus_Kelisha_SMM_PB1_2024-November.pptxCyrus_Kelisha_SMM_PB1_2024-November.pptx
Cyrus_Kelisha_SMM_PB1_2024-November.pptx
KelishaCyrus
Ìý
teacher activies un classroom and students
teacher activies un classroom and studentsteacher activies un classroom and students
teacher activies un classroom and students
prabowoedy1
Ìý
Azure Data Engineer Interview Questions By ScholarHat
Azure Data Engineer Interview Questions By ScholarHatAzure Data Engineer Interview Questions By ScholarHat
Azure Data Engineer Interview Questions By ScholarHat
Scholarhat
Ìý
Helping Autistic Girls Shine Webinar ºÝºÝߣs
Helping Autistic Girls Shine Webinar ºÝºÝߣsHelping Autistic Girls Shine Webinar ºÝºÝߣs
Helping Autistic Girls Shine Webinar ºÝºÝߣs
Pooky Knightsmith
Ìý
PUBH1000 - Module 2: Public Health History
PUBH1000 - Module 2: Public Health HistoryPUBH1000 - Module 2: Public Health History
PUBH1000 - Module 2: Public Health History
Jonathan Hallett
Ìý

Hepatic encephalopathy

  • 2. Definition • It is a state of disordered CNS function, resulting from failure of liver to detoxify toxic agents because of hepatic insufficiency and porto-systemic shunt. • It represents a reversible decrease in neurologic function. • It occurs most often in patients with cirrhosis but also occur in acute hepatic failure.
  • 3. Pathogenesis • Ammonia formed by protein breakdown in GIT • Liver liver dysfunction (abnormal) NH3 Passes BBB Hepatic encephalopathy. • Other factors: • Increase sensitivity to glutamine & GABA (inhibitory neurotransmitter) • Increase circulating levels of endogenous benzodiazepines.
  • 4. Pathogenesis (acute & chronic ) The basic cause is same in both forms but the mechanism is somewhat different Diminished detoxification of toxic intestinal nitrogenous compounds Increased in blood NH3 etc Toxic effect on brain Appearance of abnormal amines in systemic circulation Interference with neurotransmission
  • 5. Endotoxins • Ammonia. • Mercaptans (degradation of methionine in the gut) • Phenols. • Free fatty acids. • Gamma amino butyric acid(GABA) • Octopamine.
  • 6. Causes • Chronic parenchymal liver disease: • Chronic hepatitis. • Cirrhosis. • Fulminating hepatic failure: • Acute viral hepatitis. • Drugs. • Toxins e.g. Wilson’s Disease, CCL4. • Surgical Portal-systemic anastomoses, - portacaval shunts, or Transjugular intrahepatic portal-systemic shunting [TIPS]).
  • 7. Precipitating Agents • (A) Increase Nitrogen Load (a) Constipation. (b) Gastro intestinal bleeding. (c) Excess dietary intake of protein & fatty acids. (d) Azotemia.
  • 8. Precipitating Agents • (B) Infections & Trauma (Surgery) • (C) Electrolyte & Metabolic imbalance • Hypokalemia. • Alkalosis. • Hypoxia. • Hyponatremic.
  • 9. Precipitating Agents • (D) Drugs • Diuretics. • Narcotics, Tranquilizers, Sedatives.
  • 10. Clinical Features • A Disturbance in consciousness • Disturbances in sleep rhythm. • Impaired memory/ apraxia. • Mental confusion. • Apathy. • Drowsiness / Somnolence. • Coma.
  • 11. • B. Changes Personality • Childish behavior. • May be aggressive out burst. • Euphoric. • Foetor hepaticus – Foul–smelling breath associated with liver disease due to mercaptans.
  • 12. • C Neurological signs: • Flapping tremor / Asterixis (in pre coma). • Exaggerated tendon reflex. • Extensor plantar reflex.
  • 16. Investigation • Diagnosis is usually made clinically • Routine Investigations - CBC, LFTS, Electolytes, Urea, Creatinine, Prothrombin time, Albumin , A/G ratio. • Elevation of blood ammonia. • EEG (Electroencephalogram) • CSF & CT Scan – Normal.
  • 17. Differential Diagnosis • Subdural Haematoma. • Drug or Alcohol intoxication. • Wernicke’s encephalopathy. • Hypoglycaemia.
  • 18. Management • Supportive Treatment. • Specific Treatment aims at: • Decreasing ammonia production in colon • Elimination or treatment of precipitating factors.
  • 20. TREATMENT • Hospitalize the patient. • Maintain ABC. • Identify and remove the precipitating factors. • Iv fluid dextrose ,saline. • Stop Diuretic Therapy. • Correct any electrolyte imbalance. • Ryle tube feeding & bladder catheterization. • Reduce the ammonia (NH3) Load. • Diet – Restriction of protein diet. High glucose diet. • Treat Constipation by Laxatives.
  • 21. Lactulose • Lactulose 15-30ml X 3 – 4 times a day- result aims at 2-4 stools/day. • Rectal use is indicated when patient is unable to take orally. • 300ml of lactulose in 700ml of saline or sorbitol as a retention enema for 30 – 60 min. • May be repeated 4 – 6 hours.
  • 22. Mechanism of action of Lactulose • A non-absorbable disaccharide. • It produces osmosis of water- Diarrhea. • It reduces pH of colonic content & thereby prevents absorption of NH3. • It converts NH3- NH4 that can be excreted.
  • 23. Treat the GIT & other Infections Antibiotics: • Rifaximin • Broad spectrum antibiotic, recently approved in humans for HE. • Negligible systemic absorption. • Shown to decrease hospitalizations and length of stay as compared to lactulose in humans. • DOSE: 550 mg orally B.I.D
  • 24. • Metronidazole : 250mg orally T.D.S • Neomycin : 0.5 – 1 g orally 6 or 12 hours for 7 days. • Side effects: Ototoxicity, nephrotoxicity. • Vancomycin : 1 g orally B.I.D
  • 25. DIET • With held dietary protein during acute episode if patient cannot eat. • Oral intake should be 60 – 80 g/day as tolerated. • Vagetable protein is better tolerated than meat protein. • G.I.T bleeding should be controlled • 120ml of magnesium citrate by mouth or NG tube every 3 – 4 hours until stool free of blood.
  • 26. Stimulation of metabolic ammonia metabolism: • Sodium benzoate • 5 g orally twice a day. • L-ornithine-L-aspartate • 9 g orally thrice a day. • L-acyl-carnitine aspartate • 4 g orally daily. • Zinc sulphate • 600mg/day in divided doses.
  • 27. Correct amino acid metabolic imbalance • Infusion or oral administration of BCAA (branched-chain amino acid) • Its use is unnecessary except in patient who are intolerant of standard protein supplements. GABA/BZ complex antagonist: • Flumazenil ( particularly if patient has been given banzodiazepines ) • Opiods & sedatives should be avoided.
  • 28. Acarbose • α – glucosidase inhibitor. • Under study. • Other Therapies: • Prebiotics & probiotics. • Extracorporeal albumin dialysis ( MARS) • Liver transplant.
  • 29. PROGNOSIS • Acute hepatic encephalopathy may be treatable. • Chronic forms of the disorder often keep getting worse or continue to come back. • Both forms may result in irreversible coma and death. • Approximately 80% (8 out of 10 patients) die if they go into a coma. • Recovery & the risk of the condition returning vary from patient to patient
  • 30. REFERENCES • Davidson’s Principles & Practice of Medicine- 21st edition. • Harrison’s Principles of internal Medicine-10th & 17th edition. • Current Medical Diagnosis & Treatment – 2014 edition.